Enzalutamide vs Apalutamide, Darolutamide, and Bicalutamide for Nonmetastatic CRPC March 10, 2021 Tomasz Beer, MD, OHSU Knight Cancer Institute, Oregon Health and Science University, Portland, discusses results from a network meta-analysis comparing the efficacy of enzalutamide vs apalutamide, darolutamide, and bicalutamide for the treatment of nonmetastatic castration-resistance prostate cancer (CRPC).These results were presented at the virtual 2021 ASCO Genitourinary Cancers Symposium.Read the full article here. Source: Journal of Clinical Pathways Prostate Cancer News
Tomasz Beer, MD, OHSU Knight Cancer Institute, Oregon Health and Science University, Portland, discusses results from a network meta-analysis comparing the efficacy of enzalutamide vs apalutamide, darolutamide, and bicalutamide for the treatment of nonmetastatic castration-resistance prostate cancer (CRPC).These results were presented at the virtual 2021 ASCO Genitourinary Cancers Symposium.Read the full article here. Source: Journal of Clinical Pathways
Complete the Survey
